The impressive CAGR of 11.50% underscores the vital role Iloprost plays in Advanced Pulmonary Arterial Hypertension (PAH) Therapeutics. Its necessity is further highlighted by the specific growth milestones expected during the forecast period. Based on the projected CAGR, the global Ilopr